Tumor cell growth inhibition

"Tumor cell growth inhibition" is **not a canonical name for a molecular target**. Instead, it describes a desired therapeutic outcome—namely, the suppression or prevention of cancer cell proliferation. This term does not refer to a single molecule, receptor, enzyme, transporter, or any other discrete biological entity that can be directly targeted by drugs[2][3]. Rather, it encompasses numerous underlying molecular pathways and proteins that regulate cancer cell division and survival. Common **molecular targets** involved in tumor cell growth include tyrosine kinases (e.g., EGFR), serine/threonine kinases (e.g., mTOR), cyclin-dependent kinases (CDKs), PI3K/AKT/mTOR pathway components, histone deacetylases (HDACs), and others[1][2][3]. Drugs developed to inhibit these molecules—such as tyrosine kinase inhibitors (imatinib), mTOR inhibitors (everolimus), CDK4/6 inhibitors (palbociclib)—are referred to as "cancer growth blockers" or "targeted therapies"[2][3]. Because "tumor cell growth inhibition" is an effect rather than a discrete target molecule/receptor—and because it lacks specificity—it should not be used as the canonical name for structured data about therapeutic targets. For structured information purposes in pharmacology and oncology databases, you should instead identify the precise protein(s) or pathway(s) being inhibited[1][2][3].

Other names

Tumor growth inhibitionCancer cell growth inhibitionInhibition of tumor proliferation